News
EXEL
--
0.00%
--
Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030
Reportlinker.com announces the release of the report "Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030" - https://www.reportlinker.com/p06097027/?utm_source=GNW
GlobeNewswire · 1d ago
BRIEF-Exelixis Says In May, Got Notice Letters From Teva Regarding ANDA Teva Submitted To FDA
reuters.com · 2d ago
Exelixis 8-K Shows. Co. Received Notice Letters From Teva Related To Abbreviated New Drug Application For CABOMETYX Tablets; Co. Filed Complaint In US For Patent Infringement Against Teva
In May 2021, Exelixis, Inc. (“Exelixis”) received notice letters from Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Development, Inc. (collectively, “Teva”) regarding an Abbreviated New
Benzinga · 2d ago
Exelixis' Medical Chief Takes Medical Leave
MT Newswires · 5d ago
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
Zacks.com · 06/15 15:39
'Powerhouse' Exelixis initiated as a buy at H.C. Wainwright; sees 107% upside
phototechno/iStock via Getty Images Calling Exelixis (EXEL) "a powerhouse of clinical and commercial excellence," H.C. Wainwright analyst Michael King is initiating shares of the biotech with a buy rating and
Seekingalpha · 06/15 14:56
HC Wainwright & Co. Initiates Coverage On Exelixis with Buy Rating, Announces Price Target of $47
HC Wainwright & Co. analyst Michael King initiates coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and announces Price Target of $47.
Benzinga · 06/15 10:07
HC Wainwright Starts Exelixis at Buy With $47 Price Target
MT Newswires · 06/15 07:20
BRIEF-Exelixis Announces Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Evaluate Xl092 In Combination With Immuno-Oncology Therapies In Advanced Solid Tumors
reuters.com · 06/14 12:35
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced...
Business Wire · 06/14 12:00
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
--- Results from COSMIC-311 served as basis for Exelixis' recent supplemental New Drug Application to U.S. Food and Drug Administration -
Business Wire · 06/07 12:00
BRIEF-Exelixis Announces Positive Phase 2 Results For Cabometyx® (Cabozantinib) In Combination With Opdivo® (Nivolumab) In Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma At Asco 2021
reuters.com · 06/04 14:38
BRIEF-Exelixis Announces Consistent Efficacy Benefits Across Subgroups Of Phase 3 Checkmate -9Er Trial Of Cabometyx® (Cabozantinib) In Combination With Opdivo® (Nivolumab) As A First-Line Treatment For Patients With Advanced Renal Cell Carcinoma
reuters.com · 06/04 14:36
BRIEF-Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated In Analysis Of Phase 3 Checkmate -9Er Trial Of Cabometyx® (Cabozantinib) In Combination With Opdivo® (Nivolumab) In Patients With Previously Untreated Advanced Renal Cell Carcinoma
reuters.com · 06/04 14:36
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
--- Data to be presented during the 2021 American Society of Clinical Oncology's Annual Meeting -
Business Wire · 06/04 13:00
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
--- Data to be presented during the 2021 American Society of Clinical Oncology's Annual Meeting -
Business Wire · 06/04 13:00
Exelixis Announces Positive Phase 2 Results for CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
--- Data to be presented during the 2021 American Society of Clinical Oncology's Annual Meeting -
Business Wire · 06/04 13:00
Exelixis Stock Is Estimated To Be Modestly Undervalued
GuruFocus News · 06/04 12:32
These inflation winners are beating the market again this year and have potential upside
Certain stocks have a history of thriving amid higher prices — and they're beating the market again this year as inflation concerns rise.
CNBC.com · 06/02 14:25
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor conferences in June:
Business Wire · 05/26 20:15
Webull provides a variety of real-time EXEL stock news. You can receive the latest news about Exelixis through multiple platforms. This information may help you make smarter investment decisions.
About EXEL
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.